Pharmacy World & Science

, Volume 32, Issue 6, pp 730–736 | Cite as

The Pharmaceutical care of patients with type 2 diabetes mellitus

  • Anna Paula de Sá BorgesEmail author
  • Camilo Molino Guidoni
  • Lígia Domingues Ferreira
  • Osvaldo de Freitas
  • Leonardo Régis Leira Pereira
Research Article


Objective To evaluate the efficiency of pharmaceutical care on the control of clinical parameters, such as fasting glycaemia and glycosylated haemoglobin in patients with Type 2 Diabetes mellitus. Setting This study was conducted at the Training and Community Health Centre of the College of Medicine of Ribeirao Preto, University of Sao Paulo, Brazil. Methods A prospective and experimental study was conducted with 71 participants divided in two groups: (i) pharmaceutical care group (n=40), and (ii) the control group (n=31). The distribution of patients within these groups was made casually, and the patients were monitored for 12 months. Main outcome measure: Values for fasting glycaemia and glycosylated haemoglobin were collected. Results Mean values of fasting glycaemia in the pharmaceutical care group were significantly reduced whilst a small reduction was detected in the control group at the same time. A significant reduction in the levels of glycosylated haemoglobin was detected in patients in the pharmaceutical care group, and an average increase was observed in the control group. Furthermore, the follow-up of the intervention group by a pharmacist contributed to the resolution of 62.7% of 142 drug therapy problems identified. Conclusion In Brazil, the information provided by a pharmacist to patients with Type 2 Diabetes mellitus increases compliance to treatment, solving or reducing the Drug Therapy Problem and, consequently, improving glycaemic control.


Brazil Brazilian Public Health System Compliance Fasting glycaemia Glycosylated haemoglobin Pharmacist Pharmaceutical Care Type 2 Diabetes mellitus 



The authors would like to thank all the patients who participated in this study.


The study was supported by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES).

Conflicts of Interest

The authors have no conflicts of interest to disclose.


  1. 1.
    International Diabetes Federation. Diabetes Atlas. 4th ed. Brussels: International Diabetes Federation; 2009. 100p. (ISBN - 13: 978-2-930229-71-3). Available:
  2. 2.
    World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia. Geneva: World Health Organization; 2006. 52p. (ISBN - 92-4-159493-4). Available:
  3. 3.
    American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2009;32(1):S13–61.CrossRefGoogle Scholar
  4. 4.
    Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990;47(3):533–43.PubMedGoogle Scholar
  5. 5.
    Hasegawa GR. Enhancing patients’ understanding of drug therapy. Am J Health Syst Pharm. 2004;61(23):2503.PubMedGoogle Scholar
  6. 6.
    Pereira LRL, Freitas O. The evolution of pharmaceutical care and the prospect for the Brazil. Braz J Pharm Sci. 2008;44(4):601–12.Google Scholar
  7. 7.
    Castro MS, Chemello C, Pilger D, Junges F, Bohnen L, Zimmerman LM, et al. Pharmaceutical care in the management of patients with hypertension. Braz J Hypertens. 2006;13(3):198–202.Google Scholar
  8. 8.
    Lyra-Júnior DP, Kheir N, Abriata JP, Rocha CE, Santos CB, Pelá IR. Impact of pharmaceutical care interventions in the identification and resolution of drug-related problems and on quality of life in a group of elderly outpatients in Ribeirão Preto (SP), Brazil. Ther Clin Risk Manag. 2007;3(6):989–98.Google Scholar
  9. 9.
    Strand LM, Cipolle RJ, Morley PC, Frakes MJ. The impact of pharmaceutical care practice on the practitioner and the patient in the ambulatory practice setting: twenty-five years of experience. Curr Pharm Des. 2004;10(31):3987–4001.CrossRefPubMedGoogle Scholar
  10. 10.
    Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of self-reported measure of medication adherence. Med Care. 1986;24(1):67–74.CrossRefPubMedGoogle Scholar
  11. 11.
    D’agostinho RB, Grundy S, Sullivan LM, Wilson P. Validation of the Framingham coronary heart disease prediction scores: result of a multiple ethnic groups investigation. JAMA. 2001;286(2):180–7.CrossRefGoogle Scholar
  12. 12.
    Beckles GL, Engelgau MM, Narayan KM, Herman WH, Aubert RE, Williamson DF. Population-based assessment of the level of care among adults with diabetes in the US. Diabetes Care. 1998;21(9):1432–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Harris MI. Medical care for patients with diabetes. epidemiologic aspects. Ann Intern Med. 1996;124(1):117–22.PubMedGoogle Scholar
  14. 14.
    Campbell RK. Role of the pharmacist in diabetes management. Am J Health Syst Pharm. 2002;59(9):S18–21.PubMedGoogle Scholar
  15. 15.
    Clifford RM, Davis WA, Batty KT, Davis TM. Effect of a pharmaceutical care program on vascular risk factors in type 2 diabetes: the fremantle diabetes study. Diabetes Care. 2005;28(4):771–6.CrossRefPubMedGoogle Scholar
  16. 16.
    Coast-senior EA, Kroner BA, Kelley CL, Trilli LE. Management of patients with type 2 diabetes by pharmacist in primary care clinics. Ann Pharmacother. 1998;32(6):636–41.CrossRefPubMedGoogle Scholar
  17. 17.
    Davidson MB, Karlan VJ, Hair TL. Effect of a pharmacist-managed diabetes care program in a free medical clinic. Am J Med Qual. 2000;15(4):137–42.CrossRefPubMedGoogle Scholar
  18. 18.
    Maccord AD. Clinical impact of a pharmacist-management diabetes mellitus drug therapy management service. Pharmacotherapy. 2006;26(2):248–53.CrossRefGoogle Scholar
  19. 19.
    Anaya JP, Rivera JO, Lawson K, Garcia J, Luna JJ, Ortiz M. Evaluation of pharmacist-managed diabetes mellitus under a collaborative drug therapy agreement. Am J Health Syst Pharm. 2008;65(19):1841–5.CrossRefPubMedGoogle Scholar
  20. 20.
    Rothman R, Malone R, Bryant B, Horlen C, Pignone M. Pharmacist-led, primary care-based disease management improves hemoglobin HbA1c in high-risk patients with diabetes. Am J Med Qual. 2003;18(2):51–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Irons BK, Lenz RJ, Anderson SL, Wharton B, Habeger B, Anderson G. A retrospective cohort analysis of the clinical effectiveness of a physician-pharmacist collaborative drug therapy management diabetes clinic. Pharmacotherapy. 2002;22(10):1294–300.CrossRefPubMedGoogle Scholar
  22. 22.
    Odegard PS, Goo A, Hummel J, Williamas KL, Gray SL. Caring for poorly controlled diabetes mellitus: a randomized pharmacist intervention. Ann Pharmacother. 2005;39(3):433–40.CrossRefPubMedGoogle Scholar
  23. 23.
    United Kingston Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ. 1998;317(7160):703–13.Google Scholar
  24. 24.
    Chiu YW, Chang JM, Lin LI, Chang PY, Lo WC, Wu LC, et al. Adherence to a diabetic care plan provides better glycemic control in ambulatory patients with type 2 diabetes. Kaohsiung J Med Sci. 2009;25(4):184–92.CrossRefPubMedGoogle Scholar
  25. 25.
    Carvalho CV, Duarte DB, Merchán-Hamann E, Bicudo E, Laguardia J. Predictors of compliance with highly active antiretroviral therapy in Brasilia, Distrito Federal, Brazil, 1999–2000. Cad Saude Publica. 2003;19(2):593–604.CrossRefPubMedGoogle Scholar
  26. 26.
    Odegard OS, Gray SL. Barriers to medication adherence in poorly controlled diabetes mellitus. Diabetes Educ. 2008;34(4):692–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Odegard PS, Capoccia K. Medication taking and diabetes: a systematic review of the literature. Diabetes Educ. 2007;33(6):1014–29.CrossRefPubMedGoogle Scholar
  28. 28.
    World Health Organization. Adherence to long-term therapies: Evidence for action. Geneva: WHO publications; 2003. 211p. (ISBN – 92-4-154599-2). Available:
  29. 29.
    Rao D, Gilbert A, Strand LM, Cipolle RJ. Drug therapy problems found in ambulatory patient populations in Minnesota and South Australia. Pharm World Sci. 2007;29(6):647–54.CrossRefPubMedGoogle Scholar
  30. 30.
    Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and non-diabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339(4):229–34.CrossRefPubMedGoogle Scholar
  31. 31.
    Oliveira DS, Tannus LR, Matheus AS, Corrêa FH, Cobas R, Cunha EF, et al. Evaluation of cardiovascular risk according to Framingham criteria in patients with type 2 diabetes. Arq Bras Endocrinol Metabol. 2007;51(2):268–74.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2010

Authors and Affiliations

  • Anna Paula de Sá Borges
    • 1
    Email author
  • Camilo Molino Guidoni
    • 1
  • Lígia Domingues Ferreira
    • 1
  • Osvaldo de Freitas
    • 1
  • Leonardo Régis Leira Pereira
    • 1
  1. 1.Department of Pharmaceutical Sciences, College of Pharmaceutical Science of Ribeirao PretoUniversity of Sao Paulo - USPRibeirao PretoBrazil

Personalised recommendations